The FDA approved belumosudil (Rezurock, Kadmon), on 7/16/2021, for the treatment of chronic graft-versus-host disease following failure of at least 2 prior lines of systemic therapy.
Announced Research Updates
Gilead announced that patients who completed the 14-day blinded portion of the CAPELLA trial were enrolled in an open-label extension where they received lenacapavir subcutaneously every six months and an optimized background regimen. After 26 weeks, 81% (29/36) achieved an undetectable viral load (< 50 copies/mL).
Published Research Updates
In the 41 patient melanoma cohort of the open-label, Phase II, PIVOT-2 trial, treatment with bempegaldesleukin plus nivolumab resulted in an overall objective response rate of 52.6%, including 34.2% complete responses.
In the 26-week, 146 patient, Phase III, heiGHt trial, annualized height velocity was 11.2 cm/year with once weekly lonapegsomatropin compared to 11.2 cm/year with daily somatropin in treatment-naive, prepubertal patients with growth hormone deficiency.
Stay informed, subscribe to the
Prescribe Right Pharmaceutical Pipeline Tracker
Latest Tweets from Prescribe Right